Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ASGR1 | P07306 | 6/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.32 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.32 |
| ▸ | CD69 | Q07108 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542000 | 0.90 | MAPK1 (0.51) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL16135488 | 0.89 | MAPK1 (0.39) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL10209192 | 0.88 | ALDH1A1 (0.40) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL7567193 | 0.88 | ALDH1A1 (0.36) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL7886992 | 0.88 | ALDH1A1 (0.36) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL7889397 | 0.88 | ALDH1A1 (0.36) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL12762995 | 0.88 | ASGR1 (0.35) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL14217637 | 0.85 | MAPK1 (0.37) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL15258382 | 0.85 | MAPK1 (0.37) | MAPK1ALDH1A1L3MBTL1ASGR1PKM | |
| SCHEMBL5308210 | 0.84 | L3MBTL1 (0.54) | ALDH1A1L3MBTL1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399634-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | LTB4R2, LTB4R, LITAF | MAPK1 2123/4885ALDH1A1 3887/4885L3MBTL1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.